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a b s t r a c t
Prevention of ovarian cancer is the best approach for reducing the impact of this deadly disease. The
laying hen is a robust model of spontaneous ovarian cancer that recapitulates the human disease. Dietary
intervention with ﬂaxseed, the richest vegetable source of omega-3 fatty acids (OM-3FAs) and
phytoestrogen lignans, demonstrate the potential for effective prevention and amelioration of ovarian
cancer by targeting inﬂammatory prostaglandin pathways. Prostaglandin E2 (PGE2) is the most pro-
inﬂammatory ecoisanoid and one of the downstream products of two isoforms of cyclooxygenase (COX)
enzymes: COX-1 and COX-2. Our objective was to investigate the effect of ﬂaxseed supplementation for
one year on ovarian cancer and correlate its effects to expression of COX enzymes and concentrations of
prostaglandins. White Leghorn hens were fed 10% ﬂaxseed-enriched or standard diet for one year.
The severity of ovarian cancer was determined by gross pathology and histology. COX-1 and COX-2
localization and protein and mRNA expression and PGE2 and PGE3 concentrations in ovaries were
measured by IHC, western blot, quantitative real-time PCR and LC–MS–MS, respectively. The results
demonstrated a signiﬁcant reduction in late stage ovarian tumors in the ﬂaxseed-fed hens compared
with the control diet-fed hens. In correlation with decreased ovarian cancer severity, concentrations of
PGE2 and expression of COX-2 were diminished in ovaries of ﬂaxseed-fed hens. PGE3 concentrations
were below the level of detection. The results demonstrated that in normal ovaries, COX-1 was localized
to the granulosa cell layer surrounding the follicles and ovarian surface epithelium (OSE) whereas COX-2
protein was localized to the granulosa cell layer in the follicle. Extensive COX-1 and COX-2 protein
expression was found throughout the ovarian carcinoma. Our ﬁndings suggest that the ﬂaxseed-
mediated reduction in the severity of ovarian cancer in hens is correlated to the reduction in PGE2 in
the ovaries of ﬂaxseed-fed hens. These ﬁndings may provide the basis for clinical trials of dietary
intervention targeting prostaglandin biosynthesis for the prevention and treatment of ovarian cancer.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Dietary intervention with ﬂaxseed, the richest vegetable source
of n3 polyunsaturated fatty acids (n3 PUFAs) and phytoestro-
gen lignans, demonstrate the potential for effective amelioration
and prevention of ovarian cancer by targeting inﬂammatory
prostaglandin pathways.
Cyclooxygenase (COX) is the rate limiting enzyme in the produc-
tion of prostaglandins (PG) and thromboxanes. COX has two iso-
zymes, COX-1 and COX-2, which have similar structure but are
encoded with different genes (PTGS1 and PTGS2) and show distinct
expression patterns. COX-1 is known to be constitutively expressed
in many tissues and cell types and is involved in normal cellular
physiological functions, whereas COX-2 is pro-inﬂammatory in
nature and can be induced by mitogens, cytokines, tumor promoters
and growth factors [1]. Aberrantly high expression of COX-2 has been
implicated in the etiology of many forms of cancer [2]. However, we
and others have shown elevated expression of COX-1 in ovarian
cancer [3–5]. PGE2 is the most common prostaglandin found in
different human cancers including colon, lung, breast, and head and
neck cancers [6] and exerts its autocrine/paracrine effects on target
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cells by coupling to four subtypes of G-protein-coupled receptors,
which have been classiﬁed as EP1-4 [7]. EP4 is over-expressed in
many cancers such as castrate-resistant prostate cancer [8] and
colorectal cancer [9] and using EP4 antagonist inhibits breast cancer
metastasis [10].
Ovarian carcinoma is the most lethal gynecologic malignancy
and ﬁfth leading cause of cancer death in women [11]. The high
mortality rate is due to the late stage of detection when approxi-
mately 75% of ovarian cancers are diagnosed. The genetic and
molecular mechanisms underlying ovarian cancer remain largely
unknown and treatment options for patients with advanced
disease are limited. Research on ovarian cancer and development
of new therapies has been hampered due to lack of appropriate
animal models. Laying hens spontaneously develop ovarian ade-
nocarcinomas that are similar to human ovarian cancer in both
histopathology [12] and expression of some molecular markers
[5,13,14] and share similar symptoms of the disease, such as
perfuse ascites ﬂuid and peritoneal metastatic dissemination
[12,15]. Thus, the laying hen provides a tractable model for
in vivo testing of therapeutic modalities [16].
Epidemiological and preclinical studies indicate that increased
dietary intake of n3 PUFAs reduces the incidence and growth of
various cancers [17–21]. Thus, increasing the consumption of n3
PUFAs may be a nontoxic way to prevent or suppress ovarian
cancer. The n3 PUFAs include alpha-linolenic acid (ALA), eicosa-
pentaenoic acid (EPA), and docosahexaenoic acid (DHA). EPA and
DHA are both found in oily cold-water ﬁsh such as tuna and
salmon. ALA is found primarily in dark green leafy vegetables
and ﬂaxseed which is the richest plant source of n3 PUFAs. ALA
can be elongated by Δ5 and Δ6 desaturase enzymes to form EPA
and DHA in digestive tract. EPA competes with arachidonic acid for
COX enzymes and limits the production of PGE2.
Flaxseed is an excellent source of n3 PUFAs but its potential
mechanism of action on ovarian cancer is unknown. The objective
of this study was to investigate the effect of ﬂaxseed supplemen-
tation for one year on ovarian cancer and correlate its effects to
expression of COX enzymes and concentrations of prostaglandins.
Our data showed that ﬂaxseed decreases the severity of ovarian
cancer by reducing the expression of COX-2 mRNA and concentra-
tion of PGE2 in hen ovarian tissue. Therefore, our ﬁndings provide
important evidence for the use of ﬂaxseed in the chemo-
suppression and treatment of human ovarian cancer.
2. Materials and methods
2.1. Animal care
Three hundred eighty seven single comb 2.5 year old White
Leghorn hens were randomly divided into 2 groups and were fed
either a 10% ﬂaxseed-enriched diet (n¼193) or control diet
(n¼194) for one year. To ensure that incorporation of OM3-FAs
into ovaries of hens fed whole ﬂaxseed was not different than hens
fed ground ﬂaxseed, 6 hens (n¼6) were fed ground ﬂaxseed for
3 months. Ovulation frequency was measured by counting the
total number of eggs laid each week by the whole group (ﬂaxseed
or control), then dividing by the total number of hens in each
group. Hens were maintained three per cage, provided with
measured feed and water ad libitum and exposed to a photoperiod
of 17 h light/7 h dark, with lights on at 05:00 h and lights off at
22:00 h. Animal management and procedures were reviewed and
approved by the Institutional Animal Care and Use Committees at
the University of Illinois at Urbana-Champaign and University of
Illinois at Chicago.
2.2. Composition of meals
The composition of the diets has been shown previously as
supplementary data [12]. A percentage of both corn and soy were
removed from the experimental diet to keep the diet isocaloric
with the addition of the ﬂaxseed. The hens were fed 110 g of food
per day and were provided water ad libitum. Hens on the ﬂaxseed
diet consumed around 11 g of ﬂaxseed per day, or 6.2 g/kg body
weight.
2.3. Tissue collection
Hens were euthanized by CO2 asphyxiation. Upon necropsy,
ovaries were removed and small yellow follicles (6–8 mm) and
pre-ovulatory follicles (9–35 mm) were removed from normal
ovaries of the hens. Basic histology was performed [22] on
suspected abnormal ovarian tissues to conﬁrm the presence of
cancer. Tumors were classiﬁed by stage as previously reported [12]
and were characterized based on the size of the ovarian tumor,
oviductal involvement, and if there was any ascites ﬂuid and
peritoneal metastases present by gross observation.
2.4. Gas chromatography
The yolk was separated from the rest of the egg and diluted
1:25 with a phosphate buffered saline solution. A solution contain-
ing 30 mg C17:0 standard (Sigma-Aldrich), 30 mg C22:2 standard
(Sigma-Aldrich), and 200 mg butylated hydroxyl toluene (Sigma-
Aldrich) in methanol was then added to the diluted egg yolks.
Lipid extraction was performed using HPLC grade chloroform,
water and HPLC grade hexane (Sigma-Aldrich). The lipids were
then dried under a stream of nitrogen and methylated using the
Instant Metanolic HCl kit (Alltech). Then the lipids were extracted
twice with hexane. After drying under nitrogen, the lipids were
re-dissolved in hexane and injected into the Shimadzu 17A gas
chromatograph equipped with a ﬂame ionization detector. Hydro-
gen was used as the carrier gas and nitrogen as the make-up gas
with an Omegawax column. Fatty acids were determined from
their retention time and quantiﬁed by integration of area under
peak after normalization to C17:0 and C22:2 standards.
2.5. Histology and immunohistochemistry
Ovarian tissues ﬁxed in neutral buffered formalin solution were
processed and parafﬁn embedded. 5 μm sections were cut and
mounted on SuperFrost Plus microscope slides (Fisher Scientiﬁc,
IL). Slides were deparafﬁnized and rehydrated through xylene and
graded ethanol solutions (Fisher Scientiﬁc). Hematoxylin and eosin
(H&E) staining was done as described [23]. Immunohistochemistry
was performed by using the Vectastain Elite ABC kit (Vector
Laboratories, CA). Antigen retrieval was done using Antigen
Unmasking Solution (Vector Laboratories) and pressure cooked
at 20 psi for 5 min in a Decloaking Chamber electric pressure
cooker (Biocare Medical, Walnut Creek, CA). Slides were cooled
and quenched in 0.3% H2O2 (Sigma-Aldrich) in methanol for
15 min. Slides were blocked with normal serum and incubated
in anti-human COX-1 (1:50), and anti-human COX-2 (1:50) mono-
clonal antibodies (Abcam Inc., MA) overnight at 4oC. Non-immune
IgG was used for negative control. After rinsing in Tris-buffered
saline (TBS), sections were incubated with biotinylated secondary
antibody and avidin-biotin complex (Vector Laboratories). Speciﬁc
binding was visualized using DAB (Vector Laboratories) in the
presence of H2O2 and sections were counterstained with Gils
hematoxylin (Sigma-Aldrich), mounted with Histomount (Fisher
Scientiﬁc), examined on a Nikon ECLIPSE E400 microscope and
E. Eilati et al. / Prostaglandins, Leukotrienes and Essential Fatty Acids 89 (2013) 179–187180
were documented using SPOT Advanced version 4.0.1 software
(Diagnostic Instruments, Inc., Sterling Heights, MI).
2.6. Western blot
Hen ovarian tissue homogenates were prepared from snap
frozen samples, pulverized on dry ice, re-suspended in ice-cold
lysis buffer (PBS/0.1% sodium dodecyl sulfate (SDS), supplemented
with protease inhibitor cocktail HALT), and homogenized using
an Ultra-Turrax (Jenke and Kunkel, Staufen, Germany). Protein
concentrations were determined by BCA protein assay (Pierce).
Twenty micrograms of total protein were separated by SDS-PAGE
using 12.5% acrylamide/SDS separating gels and transferred to
nitrocellulose membranes as described previously [24]. Monoclo-
nal anti-human COX-1 and COX-2 (Abcam Inc., MA) and anti
human EP4 Cayman Chemical (Ann Arbor, MI, USA) were used
for detection of COX-1, COX-2 and EP4, respectively. Data were
normalized to monoclonal anti-chicken ß-Actin (Santa Cruz, CA).
Detection of bound antibody on the blot was assessed with a
horseradish peroxidase-conjugated, goat anti-mouse IgG antibody
(OuthernBiotech, Birmingham), visualized by chemiluminescent
detection (SuperSignal West Pico Chemiluminescent Substrate,
ThermoScientiﬁc, IL), and quantiﬁed after densitometry using
Imagequant software (Molecular Dynamics, CA). Data for protein
are represented as integrated OD.
2.7. RNA extraction and analysis
Ovaries preserved in RNAlater were used for RNA isolation.
Total RNA was extracted from ovaries using Trizol reagent (Invi-
trogen, CA) and was quantiﬁed by determination of absorbance at
A260. RNA samples were then treated with RQ1 RNase-free DNase
(Promega, WI) prior to reverse transcription reaction. Synthesis of
ﬁrst strand of cDNA was performed using the high capacity cDNA
Archive Kit (Applied Biosystems) and cDNA was quantiﬁed by
Quant-iT ﬂuorescent reagent (Invitrogen). Equal amounts of cDNA
from all samples were subjected to quantitative real-time PCR.
2.8. Quantitative real-time PCR (qRT-PCR)
Hen speciﬁc primers were designed to recognize target genes
using Primer Express (ABI). The primer pairs were designed so that
at least one spanned an intron. Primer sequences for COX-1
(Prostaglandin G/H synthase 1, PTGS1, XM_425326): forward: 5′
TCAGGTGGTTCTGGGACATCA 3′; reverse: 5′ TGTAGCCGTACTGG-
GAGTTGAA 3′; for COX-2 (Prostaglandin G/H synthase 2, PTGS2,
XM_422297): forward: 5′ CTGCTCCCTCCCATGTCAGA 3′; reverse: 5′
CACGTGAAGAATTCCGGTGTT 3;′ for EP4: forward 5′ GGTGTTTCA-
TAGACTGGCGA 3′; reverse: 5′ GCAGATCACCGTAACCATGA 3′; for
internal control gene GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase, GAPDH, NM_204305): forward: 5′ GATGGGTGTCAAC-
CATGAGAAA 3′; reverse: 5′ CAATGCCAAAGTTGTCATGGA 3′.
Plasmids for standards of each target of interest and internal
control GAPDH were cloned as described previously [13,25]. qRT-
PCR was conducted by amplifying cDNA with SYBRs Green
(Applied Biosystems) on ABI 7900HT using a 384 well plate format
and analyzed with AB1 Prism software. Control reactions lacking
template were run for each gene. Reactions were 10 mL in total
volume and 200 nM of each primer. The plasmid standards
and cDNA were simultaneously assayed in duplicate reactions.
The ampliﬁcation conditions were as follows: 50 1C 2 min, 95 1C
10 min, 40 cycles for 95 1C 15S, 60 1C 1 min.
2.9. Prostaglandin analysis
Hen ovarian tissue samples were homogenized and weighed
before storage in glass tubes at—80 1C. For analysis, tissue samples
were thawed, and a 300 mg sample of each was spiked with 10 μL
of d4-PGE2 in methanol/water (1:1, v/v) (100 ng/mL) as a surrogate
standard. Next, 40 μL of 1 M citric acid in water and 5 μL of 10%
BHT in hexane were added to prevent free radical-catalyzed
peroxidation. Prostaglandins were extracted by adding 6 mL of
hexane/ethyl acetate (1:1, v/v) followed by vortex-mixing for
2 min. After centrifugation at 3500 g for 10 min, the upper
organic phase was collected. The extraction procedure was
repeated, and the organic phases were combined and evaporated
to dryness under a stream of nitrogen gas. Immediately before
analysis using LC–MS–MS, each extract was reconstituted in
100 μL methanol/water (1:1, v/v) and centrifuged at 12000 g
for 10 min [26]. Normal hen ovarian tissue was used to prepare a
standard curve, and the preparation process was identical to that
of the samples. Recovery tests indicated 104712 % recovery for
two standards, PGE2 and PGE3.
2.10. Liquid chromatography–tandem mass spectrometry (LC–MS–
MS)
For the quantitative analysis of PGE2 and PGE3, HPLC separa-
tions were carried out using a Shimadzu (Columbia, MD) Promi-
nence UFLC system with a Waters (Milford, MA) XTerra MS C18
(2.150 mm, 3.5 μm) analytical column and a 5-min isocratic
mobile phase consisting of acetonitrile/ aqueous 0.1% formic acid
(37:63, v/v) at a ﬂow rate of 200 μL/min. PGE2 and PGE3 were
resolved to baseline in less than 4 min using these chromato-
graphic conditions. The HPLC system was interfaced to an Applied
Biosystems (Foster City, CA, USA) API 4000 triple quadrupole mass
spectrometer, which was operated using negative ion electrospray
[27]. The deprotonated molecules of m/z 351 and m/z 355 corre-
sponding to PGE2 and the surrogate standard d4-PGE2, respec-
tively, were selected for collision-induced dissociation at a
collision energy of 23 eV. The abundant product ions of m/z
271 andm/z 275, corresponding to the [M–H–2H2O–CO2]– product
ions of PGE2 and d4-PGE2, respectively, were measured using
selected reaction monitoring [28]. Likewise, selected reaction
monitoring of the transition of m/z 349 to m/z 269 was used
for quantitative analysis of PGE3. The retention times of PGE3,
PGE2 and d4-PGE2, were 2.33, 3.09, and 3.01 min, respectively.
For quantitative analysis using LC–MS–MS with SRM, the injection
volume was 10 mL. The standard curves for PGE2 and PGE3 were
linear (r240.999) over the concentration range of 0.1–100 ng.
2.11. Statistical analysis
Statistical analysis was performed with GraphPad InStat by
using One-way ANOVA with Student-Newman–Keuls comparison
and also 2-way Contingency Table and Chi-Square Tests. A value of
Po0.05 was considered signiﬁcant whereas a value of Po0.01
was considered as highly signiﬁcant.
3. Results
3.1. Ovarian cancer severity
More late stage tumors with ascites ﬂuid and metastasis were
presented in hens fed the control diet compared with hens fed
the ﬂaxseed enriched diet (Fig. 1A and B; 61% vs. 47%; Po0.05).
In contrast, the hens fed the ﬂaxseed diet had more early stage
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tumors that were conﬁned to the ovary and oviduct indicative of
the chemo-suppressive effect of ﬂaxseed.
3.2. Egg laying frequency
The ovulation rate (egg laying frequency) was not changed
under the effect of the ﬂaxseed enriched diet (Fig. 1C) indicating
that the reduction in ovarian cancer severity in hens fed the
ﬂaxseed diet is not due to lower number of laid eggs.
3.3. Fatty acid analysis
The incorporation of n3 PUFAs into tissue was measured
using gas chromatography. Six egg yolks at the three and twelve
month time points from hens in both ﬂaxseed and control diet
groups were used. The total amount of n3 PUFAs in yolks
collected from the whole ﬂaxseed-fed hens for 3 months was
not signiﬁcantly different than total amount of n3 PUFAs in yolks
collected from the ground ﬂaxseed-fed hens for 3 months
(Fig. 1D); however, yolks collected from the hens fed both whole
ﬂaxseed and ground ﬂaxseed had higher incorporation of n3
PUFAs compared with hens fed the control diet (Po0.05). The egg
yolks collected from the whole ﬂaxseed-fed hens for one year had
higher amounts of ALA, EPA and DHA compared with yolks from
the control diet-fed hens for a year (Fig. 1E–G; Po0.05).
3.4. Localization of COX-1 and COX-2 in the hen ovary
The distribution of COX-1 and COX-2 proteins in the hen ovary
was examined by immunohistochemistry. Increased expression of
COX-1 protein was observed in cancerous ovaries (Fig. 2C and D)
compared to normal ovaries (Fig. 2A and B) of hens in both control
and ﬂaxseed groups. In the normal ovaries, COX-1 was seen mostly
in the granulosa cell layer (arrow) surrounding the follicles and in
ovarian surface epithelial cell layer (Fig. 2A and B); however
extensive COX-1 protein expression was found throughout the
ovarian carcinoma (Fig. 2C and D). COX-2 protein was expressed in
a similar pattern to COX-1. In normal ovaries (Fig. 3A and B), COX-2
expression was mostly seen in the granulosa cell layer of the
follicles; whereas in cancerous ovaries, COX-2 was widely distrib-
uted over the tissue (arrow, Fig. 3C and D).
3.5. COX protein expression
COX-1 and COX-2 protein expression in ovaries of hens from
both control and ﬂaxseed groups were quantiﬁed by western blot
(Fig.4A–D). COX-1 protein expression was signiﬁcantly increased
in cancerous ovaries compared to normal ovaries, independent of
diet (Po0.05). There was no statistical difference in COX-2 protein
expression between cancerous ovaries of the control diet-fed hens
and cancerous ovaries of the ﬂaxseed diet-fed hens (Fig. 4B and D).
However, there was a signiﬁcant decrease in COX-2 protein
expression in normal ovaries of the ﬂaxseed-fed hens compared
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Fig. 1. (A) and (B) There was a reduction in the severity of the disease in ﬂaxseed-fed hens. Hens fed the ﬂaxseed enriched diet had more early stage ovarian tumors which
were still conﬁned to the ovary (Po0.05). Hens on the control diet had more late stage tumors and the cancer had spread to other organs (Po0.05). (C) Egg laying frequency
is unaffected by the addition of ﬂaxseed to the diet. There were no signiﬁcant differences in the numbers of eggs laid in the ﬂaxseed-fed group compared to the control
group. (D) There was a signiﬁcant increase in total n3 PUFAs in egg yolks collected from the ﬂaxseed-fed hens (both ground and whole) for 3 month compared to hens fed
control diet for 3 month (n¼6; Po0.05). There was no statistically signiﬁcant difference between total n3 PUFAs in egg yolks collected from hens fed ground ﬂaxseed
versus whole ﬂaxseed. (E)–(G) The yolks from the ﬂaxseed-fed hens for one year had higher ALA, EPA and DHA compared to yolks collected from the control diet fed hens
(Po0.05). *Po0.05.
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with the normal ovaries of the control-fed hens indicating that
ﬂaxseed decreases COX-2 protein expression in normal ovaries of
hens (Po0.05; Fig. 4A and D).
3.6. COX mRNA expression
To determine if the observed changes in COX protein expres-
sion in ovaries are transcriptionally regulated, COX-1 and COX-2
mRNA expression were measured in normal and cancerous ovaries
of hens fed the ﬂaxseed enriched and control diet by qRT-PCR.
COX-1 mRNA expression was signiﬁcantly higher in cancerous
ovaries compared to normal ovaries, independent of the diet
(Po0.01; Fig. 4E). There was no signiﬁcant difference in COX-1
mRNA expression between cancerous ovaries of hens fed the
ﬂaxseed enriched diet and cancerous ovaries of hens fed the
control diet. In contrast, we observed a signiﬁcant inhibition of
COX-2 mRNA expression in both normal and cancerous ovaries of
hens fed the ﬂaxseed enriched diet compared to normal and
 Flaxseed Diet Control Diet
Normal
Cancer
Fig. 2. COX-1 immunohistochemistry; (A) normal ovary of the control-fed hens; (B) normal ovary of the ﬂaxseed-fed hens, arrows in A and B point to granulosa cell layer
stained by COX-1; (C) ovarian tumor of the control-fed hens (inset: non-immune IgG, 20X); (D) ovarian tumor of the ﬂaxseed-fed hens. Calibration bar, 50 mm.
 Flaxseed Diet Control Diet
Normal
Cancer
Fig. 3. COX-2 immunohistochemistry: (A) normal ovary of the control-fed hens, (inset: non-immune IgG, 20X); (B) normal ovary of the ﬂaxseed-fed hens, arrows in A and B
point to granulosa cell layer stained by COX-2; (C) ovarian tumor of the control-fed hens; (D) ovarian tumor of the ﬂaxseed-fed hens, arrows in C and D point to punctate-
located COX-2. Calibration bar for A & B: 100 mm, Calibration bar for C and D: 50 mm.
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cancerous ovaries of hens fed the control diet, respectively
(Po0.001; Fig. 4F). COX-2 mRNA expression was similar between
cancerous and normal ovaries of hens fed the ﬂaxseed diet for one
year indicating that the ﬂaxseed diet is targeting COX-2 at the
transcriptional level.
3.7. Prostaglandins
The levels of PGE2 and PGE3 were measured by LC–MS–MS in
normal and cancerous ovaries of hens fed the ﬂaxseed and con-
trol. The cancerous ovaries of hens had higher concentrations of
PGE2 compared with normal ovaries, regardless of diet (Fig. 5).
The results indicated that consumption of a ﬂaxseed enriched diet
for one year signiﬁcantly reduces the concentrations of PGE2 in
both normal and cancerous ovaries of hens compared to normal
and cancerous ovaries of hens fed the control diet, respectively.
PGE3 concentrations were below the level of detection (data not
shown).
3.8. Effect of ﬂaxseed on EP4 expression in ovaries
There were no signiﬁcant differences in expression of EP4
mRNA and protein among groups indicating that existence of
cancer or ﬂaxseed supplementation does not affect the expression
of EP4 in ovaries of hens (Fig. 6).
4. Discussion
PGE2 is the most pro-inﬂammatory lipid and plays an impor-
tant role in cancer therefore suppressing its pathway may be a
suitable target to prevent/suppress ovarian cancer. We fed hens a
10% ﬂaxseed enriched diet for one year and investigated its effect
on ovarian cancer. Our results indicated that feeding the laying
hens with a ﬂaxseed enriched diet for one year decreased the
severity of ovarian cancer but the mechanism by which ﬂaxseed
supplementation suppresses ovarian cancer severity was
unknown. Thus, we postulate that feeding the hens with ﬂaxseed
reduces the expression of COX enzymes and PGE2 concentrations
COX-2
COX-1
Flaxseed normal ovarian tissueControl normal ovarian tissue
β-actin
COX-1
Flaxseed ovarian cancer tissueControl ovarian cancer tissue
β-actin
COX-2
1
COX-2 Protein
0.18
COX-1 Protein
0.4
0.6
0.8
*
0.06
0.09
0.12
0.15
*
0
0.2
In
te
gr
at
ed
 O
pt
ic
al
 D
en
si
ty
COX-1 mRNA COX-2 mRNA
0
0.03
Control Normal Control Cancer Flax Normal Flax Cancer
Control Normal Control Cancer Flax Normal Flax Cancer
Control Normal Control Cancer Flax Normal Flax Cancer
Control Normal Control Cancer Flax Normal Flax Cancer
15
20
25
**
**
30
40
50
0
5
10
C
O
X
-1
/G
A
PD
H
0
10
20
C
O
X
-2
/G
A
PD
H
*** ***
*
Fig. 4. Western blot and qPCR for COX-1 and COX-2 in ovaries of hens from both control and ﬂaxseed groups. (A)–(C) COX-1 protein expression was signiﬁcantly higher in
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in ovaries and thereby decreases the severity of ovarian cancer.
Here we report that the reduced ovarian cancer severity in hens
fed the ﬂaxseed enriched diet for one year is correlated to
decreased concentration of prostaglandin E2 and COX-2 in the
ovaries of hens.
Reduction in ovulation results in a decrease in ovarian cancer
[29]. This raises the question: is the reduced severity that we
observed in this study due to a decrease in ovulation rate?
Therefore, we monitored the egg laying (ovulation) rate and the
data showed that the ﬂaxseed enriched diet does not change
the ovulation rate compared with the control diet indicating that
the reduced ovarian cancer severity in hens fed the ﬂaxseed diet is
not due to reduction in ovulation.
Incorporation of n3 PUFAs into egg yolks of ﬂaxseed-fed hens
provides a non-invasive measure of the incorporation of n3
PUFAs into ovaries of the hens. Our data indicated that incorpora-
tion of n3 PUFAs into egg yolks of hens fed ground ﬂaxseed is
not statistically different than incorporation of n3 PUFAs into
egg yolks of hens fed whole ﬂaxseed. Thus, hens in this study were
fed a diet supplemented with 10% whole ﬂaxseed. Higher amounts
of ALA, EPA and DHA in egg yolks of the hens fed ﬂaxseed were
detected compared to yolks collected from the control diet-fed
hens. Our data indicated that the hens were able to incorpo-
rate high amounts of n3 PUFAs from ﬂaxseed into their eggs.
This was in agreement with a study published by Scheideler et al.
that showed 10% ﬂaxseed diet increased the incorporation of n3
PUFAs into the eggs [30].
We detected higher expression of COX-1 protein and mRNA in
cancerous ovaries compared with normal ovaries, regardless of
diet. Hales et al. reported that COX-1 is over-expressed in ovarian
cancer in hens [5] and Urick et al. reported that increased COX-1
expression in hen ovaries with tumors was correlated to increased
PGE2 levels [4]. In present study, the expression of COX-1 was
localized to the granulosa cell layers and conﬁned to the OSE and
cortical stroma adjacent to the follicle in normal ovaries. This was
in agreement with previous studies conducted in rats [31] and
hens [5] that have shown COX-1 is constitutively expressed in the
ovary and conﬁned to interstitial thecal cells.
There are many reports on the role of COX-2 enzyme and its
over-expression in cancer. In the mammalian ovary, COX-2 is
localized to the granulosa cells and induced by luteinizing hor-
mone at the time of the preovulatory gonadotropin surge [32].
In the hen ovary, COX-2 is expressed in the granulosa cells, but
distinct from the reported distribution in the mammalian ovary,
COX-2 is also highly expressed in the interstitial tissue of the ovary
[4,5]. Because chickens have a high ovulation frequency, high
expression and accumulation of COX-2 in hen ovaries are possible.
Our data indicated that COX-2 expression in ovarian carcinoma
becomes more localized to discrete foci, trapped within the
glandular like structures of the ovarian tumor. Arico et al. reported
that COX-2 can induce angiogenesis via vascular endothelial
growth factor (VEGF) and prostaglandin production and can also
inhibit apoptosis [33]. Therefore, COX-2 may be a plausible target
for the prevention and treatment of ovarian cancer. One feasible
way to blunt the cancer-promoting activity of COX-2 is to limit its
access to arachidonic acid, the precursor for the prostaglandins
which mediate this activity. Flaxseed contains high amounts of
ALA which can be converted to EPA and DHA. EPA can act as a
competitive inhibitor of arachidonic acid binding to COX-2 [34].
There was a signiﬁcant decrease in COX-2 mRNA expression in
both normal and cancerous ovaries of ﬂaxseed-fed hens compared
to hens fed the control diet. However, there was no similar
reduction observed in the expression of COX-2 protein in ovaries
of hens in any of the groups. The lack of correlation between COX-
2 mRNA and protein expression has been previously reported. Kim
et al. has shown that HuR knockdown colon cancer cells have
reduced COX-2 mRNA levels which did not lead to a reduction in
COX-2 protein levels [35]. Furthermore, the semi-quantitative
identiﬁcation of COX-2 protein by IHC or western blot does not
necessarily correlate with enzymatic activity [36]. The data sug-
gest that ﬂaxseed is a speciﬁc COX-2 inhibitor at the transcrip-
tional level and may also inhibit COX-2 activity by substrate level
modulation. The ﬂaxseed-mediated inhibition in COX-2 is likely
important to the mechanisms of action of ﬂaxseed in the reduction
of ovarian cancer in our study. Our data are in agreement with
previous studies which have shown the inhibition of COX-2 by
n3 PUFAs [37–39].
High concentrations of PGE2 are believed to be immunosup-
pressive [40], increase angiogenesis [41], stimulate cell prolifera-
tion and inhibit apoptosis in ovarian cancer cell lines [42]. PGE2
mediated immune suppression may lead to increased susceptibil-
ity to tumor formation and impaired defense against previously
formed tumors [4,43]. The inﬂuence of PGE2 pathway on contri-
buting factors in tumor formation and progression is clear;
however, the mechanisms by which the n3 PUFAs inhibit PGE2
pathway remains to be fully elucidated. Our results indicated that
a ﬂaxseed enriched diet signiﬁcantly reduces the levels of PGE2 in
ovaries of hens compared to ovaries of hens fed the control diet.
This might be due to down-regulation of COX-2 at the transcrip-
tion level, and to the substrate-level modulation of the enzymatic
activity of both COX enzymes. The arachidonic acid (AA) is the
predominant substrate for both COX enzymes. Dietary n3 PUFA
may modulate substrate pools available to COXs and lipoxygenases
(LOX), thereby controlling the formation of downstream eicosa-
noids such as PGE2 [44]. The EPA can compete with AA and act as
an alternative substrate for COX enzymes [45] and decrease PGE2.
The ability of ﬂaxseed to suppress ovarian cancer growth might
be due to reducing proliferation and increasing apoptosis in
ovarian tumors via diminishing PGE2 concentrations. Furthermore,
ovarian tumors with high tissue contents of PGE2 have a weak
response to chemotherapy [46], therefore, a ﬂaxseed enriched diet
not only may prevent progression of cancer, but it may increase
the sensitivity of tumors to chemotherapy. Moreover, it is likely
that anti-estrogenic properties of lignans play role in anti-cancer
effects of ﬂaxseed.
EP4 receptor promotes tumor progression by increasing pro-
angiogenic factor and tumor cell invasiveness in ovarian carcinoma
cell lines. Spinella et al. reported that EP2–EP4 signaling regulates
vascular endothelial growth factor production and ovarian carci-
noma cell invasion [47]. However, we did not detect a high
expression of EP4 in ovaries with high concentration of PGE2.
It might be due to use of in vivo model instead of ovarian cell lines.
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Fig. 5. Prostaglandin E2 (PGE2) concentrations in hen ovarian tissues were
measured by LC–MS–MS. The cancerous ovaries of hens had higher concentrations
of PGE2 compared with normal ovaries, regardless of diet. Flaxseed reduced the
concentrations of PGE2 in normal and cancerous ovaries of the ﬂaxseed-fed hens
compared with normal and cancerous ovaries of the control-fed hens, respectively.
a vs b and c vs d, Po0.05; a vs c and b vs d Po0.01.
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Our study demonstrated that consumption of 10% ﬂaxseed
enriched diet for one year does not affect expression of EP4
neither at the level of transcription nor translation.
Taken together, the present results indicate that the ﬂaxseed
mediated reduction in the severity of ovarian cancer in hens [12] is
correlated to the ﬂaxseed-mediated reduction in PGE2. The reduc-
tion in PGE2 appears to be primarily due to inhibition of COX-2,
and it is likely that substrate modulation of both COX enzymes
further contributes to the reduction in PGE2 levels. Concomitant
ﬂaxseed mediated reduction in PGE2 and ovarian cancer severity
suggests that inﬂammatory prostaglandins drive the progression
of the disease; therefore PGE2 may be an effective target for the
reduction of ovarian cancer. We have previously shown that
exactly at the age that ovarian cancer is ﬁrst detected in chickens,
PGE2 levels increase indicating cumulative inﬂammation may also
contribute to initiation of ovarian cancer [48]. We have recently
shown that life-long consumption of ﬂaxseed reduces not only the
severity but also the incidence of ovarian cancer in hens [49].
In conclusion, our study provides new insight into the mechanism
of action of ﬂaxseed in the reduction of ovarian cancer severity
and will establish the foundation for clinical trials to test the
efﬁcacy of dietary intervention with ﬂaxseed for the prevention
and suppression of ovarian cancer in women.
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